| Oxidative phosphorylation |
1.81 |
7.01e-2 |
93/133 (69.92%) |
ATP5MC3;NDUFAB1;ATP5F1C;...
|
| Vibrio cholerae infection |
1.74 |
1.10e-1 |
44/50 (88%) |
ACTB;KCNQ1;ATP6V0C;...
|
| Ribosome |
1.62 |
2.72e-1 |
113/158 (71.52%) |
RPL26L1;RPL26;RPS5;...
|
| Fc gamma R-mediated phagocytosis |
1.58 |
3.24e-1 |
79/97 (81.44%) |
CDC42;BIN1;LYN;...
|
| Metabolism of xenobiotics by cytochrome P450 |
1.57 |
2.80e-1 |
49/77 (63.64%) |
CYP1B1;UGT2B28;ALDH3A1;...
|
| Proteasome |
1.54 |
2.80e-1 |
44/46 (95.65%) |
PSMA6;PSMB4;PSMD14;...
|
| Nucleotide excision repair |
1.54 |
2.42e-1 |
40/47 (85.11%) |
CETN2;RPA3;RFC3;...
|
| Mismatch repair |
1.53 |
2.39e-1 |
22/23 (95.65%) |
RPA3;RFC3;RFC4;...
|
| DNA replication |
1.52 |
2.31e-1 |
34/36 (94.44%) |
RPA3;RFC3;POLE3;...
|
| Cell cycle |
1.51 |
2.34e-1 |
110/124 (88.71%) |
MAD2L1;TFDP2;PTTG1;...
|
| Ubiquinone and other terpenoid-quinone biosynthesis |
1.48 |
2.76e-1 |
9/11 (81.82%) |
NQO1;COQ7;HPD;...
|
| Thiamine metabolism |
1.48 |
2.56e-1 |
12/15 (80%) |
AK4;TPK1;AK1
|
| Leukocyte transendothelial migration |
1.47 |
2.52e-1 |
90/114 (78.95%) |
CDC42;CTNNB1;CD99;...
|
| Basal transcription factors |
1.47 |
2.48e-1 |
37/45 (82.22%) |
TBPL1;TAF9B;GTF2A2;...
|
| Pentose phosphate pathway |
1.43 |
3.19e-1 |
25/30 (83.33%) |
PFKL;G6PD;PRPS2;...
|
| Neutrophil extracellular trap formation |
1.42 |
3.30e-1 |
101/189 (53.44%) |
HAT1;MPO;ACTB;...
|
| Pentose and glucuronate interconversions |
1.41 |
3.51e-1 |
17/34 (50%) |
SORD;UGT2B28;CRYL1;...
|
| Huntington disease |
1.40 |
3.45e-1 |
233/306 (76.14%) |
ITPR1;ATP5MC3;PSMA6;...
|
| Primary bile acid biosynthesis |
1.40 |
3.37e-1 |
15/17 (88.24%) |
SLC27A5;CH25H;AMACR;...
|
| Butanoate metabolism |
1.39 |
3.37e-1 |
23/28 (82.14%) |
BDH1;ABAT;HMGCL;...
|
| Fanconi anemia pathway |
1.39 |
3.33e-1 |
36/54 (66.67%) |
HES1;RPA3;RMI1;...
|
| Glutathione metabolism |
1.37 |
3.57e-1 |
43/57 (75.44%) |
GSTO1;GSTP1;HPGDS;...
|
| Parkinson disease |
1.37 |
3.49e-1 |
176/249 (70.68%) |
ITPR1;ATP5MC3;PSMA6;...
|
| Peroxisome |
1.37 |
3.37e-1 |
72/82 (87.8%) |
PHYH;PEX3;PEX11A;...
|
| Spliceosome |
1.35 |
3.65e-1 |
101/150 (67.33%) |
BUD31;PUF60;LSM5;...
|
| Tight junction |
1.34 |
3.76e-1 |
130/169 (76.92%) |
CDC42;CLDN8;CLDN10;...
|
| Retrograde endocannabinoid signaling |
1.30 |
3.98e-1 |
118/148 (79.73%) |
ITPR1;GNG7;NDUFAB1;...
|
| Synthesis and degradation of ketone bodies |
1.29 |
4.01e-1 |
9/10 (90%) |
BDH1;HMGCL;HMGCS2
|
| Phagosome |
1.29 |
3.97e-1 |
118/152 (77.63%) |
MPO;CORO1A;ACTB;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
1.29 |
3.87e-1 |
62/70 (88.57%) |
CDC42;LYN;ATP6V0C;...
|
| Longevity regulating pathway |
-1.31 |
4.06e-1 |
90/151 (59.6%) |
CAMKK2;RB1CC1;PIK3R2;...
|
| Glycosaminoglycan biosynthesis |
-1.31 |
4.02e-1 |
40/58 (68.97%) |
DSE;CSGALNACT2;B4GALT2;...
|
| Human papillomavirus infection |
-1.32 |
4.11e-1 |
284/331 (85.8%) |
IFNAR2;PPP2R5A;ITGB5;...
|
| Staphylococcus aureus infection |
-1.33 |
3.98e-1 |
72/95 (75.79%) |
HLA-DOB;C3;CFH;...
|
| Riboflavin metabolism |
-1.34 |
4.06e-1 |
7/8 (87.5%) |
ACP2;ENPP1
|
| Viral myocarditis |
-1.34 |
4.01e-1 |
53/60 (88.33%) |
HLA-DOB;CXADR;CASP3;...
|
| Mannose type O-glycan biosynthesis |
-1.35 |
3.98e-1 |
14/23 (60.87%) |
LARGE1;POMT2;POMT1;...
|
| Breast cancer |
-1.35 |
4.10e-1 |
119/147 (80.95%) |
IGF1;TCF7L2;FGF21;...
|
| HIF-1 signaling pathway |
-1.37 |
4.09e-1 |
105/109 (96.33%) |
CAMK2B;LTBR;PFKFB3;...
|
| Amoebiasis |
-1.38 |
3.92e-1 |
99/102 (97.06%) |
PLCB1;LAMA4;IFNG;...
|
| Small cell lung cancer |
-1.40 |
3.47e-1 |
90/92 (97.83%) |
RXRB;BCL2L1;BIRC2;...
|
| Dilated cardiomyopathy |
-1.42 |
3.20e-1 |
86/96 (89.58%) |
AGT;TPM1;TTN;...
|
| Gastric cancer |
-1.43 |
3.31e-1 |
122/149 (81.88%) |
RXRB;ARAF;TGFB3;...
|
| PI3K-Akt signaling pathway |
-1.47 |
2.52e-1 |
317/354 (89.55%) |
BCL2L1;IFNAR2;EIF4B;...
|
| Ascorbate and aldarate metabolism |
-1.48 |
2.59e-1 |
15/30 (50%) |
UGT2B15;UGT2A3;ALDH2;...
|
| Arrhythmogenic right ventricular cardiomyopathy |
-1.49 |
2.62e-1 |
70/77 (90.91%) |
TCF7L2;ACTN3;CACNA1F;...
|
| Adipocytokine signaling pathway |
-1.49 |
2.71e-1 |
64/69 (92.75%) |
TNF;RXRG;JAK2;...
|
| Type II diabetes mellitus |
-1.51 |
2.36e-1 |
42/46 (91.3%) |
SOCS1;TNF;CACNA1G;...
|
| MicroRNAs in cancer |
-1.54 |
1.98e-1 |
146/310 (47.1%) |
RDX;CREBBP;CRKL;...
|
| Calcium signaling pathway |
-1.54 |
2.16e-1 |
213/240 (88.75%) |
EGFR;ADCY3;FGF9;...
|
| Malaria |
-1.58 |
1.70e-1 |
44/50 (88%) |
KLRK1;TGFB3;TNF;...
|
| Glycerolipid metabolism |
-1.59 |
1.82e-1 |
44/61 (72.13%) |
MBOAT2;LPIN2;ALDH3A2;...
|
| Focal adhesion |
-1.61 |
1.72e-1 |
180/201 (89.55%) |
THBS4;FLNC;ITGA2;...
|
| Proteoglycans in cancer |
-1.62 |
1.81e-1 |
172/205 (83.9%) |
CAMK2B;EIF4B;ARAF;...
|
| Fatty acid degradation |
-1.66 |
1.43e-1 |
40/43 (93.02%) |
ACSL5;ACAA2;ALDH2;...
|
| PPAR signaling pathway |
-1.69 |
1.16e-1 |
66/74 (89.19%) |
RXRG;CYP7A1;SCD;...
|
| Legionellosis |
-1.72 |
1.17e-1 |
51/57 (89.47%) |
PYCARD;NAIP;HSF1;...
|
| Estrogen signaling pathway |
-1.76 |
1.18e-1 |
119/137 (86.86%) |
CALML3;AKT1;ADCY9;...
|
| Regulation of lipolysis in adipocytes |
-1.79 |
1.20e-1 |
52/55 (94.55%) |
AKT1;ADCY9;ADRB2;...
|
| ECM-receptor interaction |
-1.87 |
1.03e-1 |
80/88 (90.91%) |
THBS4;ITGA2;COMP;...
|
